EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

PetVivo Holdings Inc (PETV) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of PetVivo Holdings Inc $0.14, price $0.75, upside -81.9%, quality 16 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US7168174081

PH PetVivo Holdings Inc logo Thin data Oct 4, 2026

PetVivo Holdings Inc

PETV · US

Weakest SetupStrongly overvalued and low quality.

Low debt
Mixed Growth (revenue 5y +146.4 %/yr in USD)
Fair value $0.1360 · Strongly overvalued (−81.9%)
Quality 16/100
Negative free cash flow
Trails peers (2/9)
Narrow moat 3/100
Thin data
⚠ Dilution

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$13.99 $0.3510 Fair Value $0.1360 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.

How to read this chart

60‑month range $0.3510 – $13.99 · fair‑value band $0.0765 – $0.1870 · the $0.7500 price screens above the $0.1360 fair value. Dashed = 300-day average. As of Oct 4, 2026.

Follow PetVivo Holdings in your weekly email

Every Wednesday you see whether PetVivo Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.

Show more

PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.

Stock analysis

PetVivo Holdings Inc (PETV) currently trades at $0.7500, while our model-based Fair Value estimate is $0.1360, 81.9% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of $0.1600 per share, and 0 of the 3 models we run sit above the $0.7500 price.

Bear case: the Asset-Based group reads lowest at $0.0400, and 3 of the 3 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0765 (bear) to $0.1870 (bull), the price of $0.7500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

PetVivo Holdings Inc reported revenue of $1.1M in FY2026 versus $116K in FY2022, a compound +77.3%/yr. Reported net income was −$10.5M in FY2026.

Key figures

Market cap $27.8M · P/S ratio 24.1 · EPS (TTM) $−0.3300 · Dividend yield 1.4% · Return on equity −384% · Return on assets (EBIT) −216% · Operating margin −477% · Revenue (TTM) $1.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −82%, PETV screens richer than that median.

Fair Value models

Bear $0.0765 Fair Value $0.1360 Bull $0.1870
Price $0.7500 · Upside -81.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM $0.0900 $0.1900 $0.2800 64
DDM Multi-Stage $0.0900 $0.1600 $0.2000 64
NCAV (Graham) $0.0300 $0.0400 $0.0600 54
All 3 models by family
Dividend Discount
Gordon GGM $0.0900 $0.1900 $0.2800 64
DDM Multi-Stage $0.0900 $0.1600 $0.2000 64
Asset-Based
NCAV (Graham) $0.0300 $0.0400 $0.0600 54

Open the full fair value analysis →

Notify me when PETV reaches fair value

Put PETV on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 16/100

Of which business quality 21 · Market factors (momentum, volatility) 19

Profitability 11
Margins and returns on capital today
Quality Growth 24
Are margins and returns improving?
Cashflow 2
Earnings quality: real cash, not paper profit
Fin. Strength 51
Balance sheet, leverage, solvency risk
Investment 44
Disciplined investing over empire-building
Low Volatility 17
Calm price path (market factor)
Momentum 24
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+146.4%
Start year 2021 (pandemic). Over 10 years: +31.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15,574.7% (2021) → −706.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

PETV screens overvalued: fair value 82% below the price. Compare with Abbott Laboratories, →

Compare PetVivo Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 336 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 16 · Bottom 25%
Fair Value upside −81.9% · Bottom 25%
Profitability
Return on assets −102.4% · Bottom 25%
Growth and dividend
Revenue growth 13.5% · Above median
Dividend yield (TTM) 1.4% · Below median
Balance sheet
Debt / equity 0.00× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 12.64× · Priciest 25%
P/S (TTM) 23.52× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)68 · sector 31
PAST (return on equity)0 · sector 16
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)28 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $85.36 $93.90 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "PetVivo Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/PETV

Frequently asked questions

Is PetVivo Holdings Inc (PETV) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $0.1360 versus a price of $0.7500, about −82% upside (overvalued).
What is the fair value of PETV?
Our model-based fair value for PetVivo Holdings Inc is $0.1360 (as of Oct 4, 2026), built from audited fundamentals. The current price: $0.7500.
What is the quality score of PETV?
PetVivo Holdings Inc has a Quality Score of 16/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PetVivo Holdings Inc (PETV)?
Our model-based price target is the fair value of $0.1360 (as of Oct 4, 2026) from 3 valuation models. Cautious scenario $0.0765, optimistic scenario $0.1870. It is a calculation from audited fundamentals, not an analyst target.
What is the PetVivo Holdings Inc stock forecast for 2026?
Our models put fair value at $0.1360, about −82% upside versus a price of $0.7500 (overvalued). Cautious scenario $0.0765, optimistic scenario $0.1870. The calculation is refreshed regularly with new filings.
What is the revenue of PetVivo Holdings Inc (PETV)?
PetVivo Holdings Inc reported trailing-twelve-month revenue of about $1.2M (latest available figure, as of Oct 4, 2026).
Does PetVivo Holdings Inc pay a dividend?
PetVivo Holdings Inc currently shows a dividend yield of about 1.42% relative to its recent price (as of Oct 4, 2026).
What is the intrinsic value of PetVivo Holdings Inc (PETV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PetVivo Holdings Inc it is $0.1360 per share (as of Oct 4, 2026), against a price of $0.7500. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is PetVivo Holdings Inc stock overvalued or undervalued in 2026?
As of Oct 4, 2026, PETV trades above its calculated fair value: price $0.7500, fair value $0.1360, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PETV?
No. The price is what the market pays today ($0.7500); the fair value is what the company's own numbers justify ($0.1360). For PetVivo Holdings Inc the two are $0.6140 per share apart. That gap is exactly why we show both numbers side by side.
How much is PetVivo Holdings Inc worth?
The market values PetVivo Holdings Inc at about $27.8M (market capitalisation, as of Oct 4, 2026). Per share that is $0.7500; our models calculate a fair value of $0.1360 per share.
What do the bullish and bearish scenarios say about PETV?
Our models span a range for PetVivo Holdings Inc: cautious scenario $0.0765, base $0.1360, optimistic $0.1870 per share (as of Oct 4, 2026, price $0.7500). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PetVivo Holdings Inc (PETV)?
Balance-sheet figures for PetVivo Holdings Inc (as of Oct 4, 2026): return on equity −384.4%, debt of 0.00 per unit of equity. They feed the Quality Score of 16/100, which measures business quality independently of the share price.
How far is PETV from its 52-week high?
PetVivo Holdings Inc trades at $0.7500, about 50% below its 52-week high of $1.50 and 20% above the low of $0.6236 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1360 is for.
Which stocks are comparable to PetVivo Holdings Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PetVivo Holdings Inc stock attractive at the current price?
The data as of Oct 4, 2026: price $0.7500, calculated fair value $0.1360 (−82%), Quality Score 16/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PETV calculated?
We run PetVivo Holdings Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1360, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. PetVivo Holdings Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PetVivo Holdings Inc (PETV)?
The closing price on Oct 2, 2026 was $0.7500. Our model-based fair value is $0.1360, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PetVivo Holdings Inc right now?
The price sits above even our optimistic bull case ($0.1870). The favourable scenario is already priced in. Weak quality (16/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0765 to $0.1870) leaves room in how you read the outcome.

Key figures of PetVivo Holdings Inc

How large is the market capitalisation of PetVivo Holdings Inc (PETV)?
The market capitalisation of PetVivo Holdings Inc is $27.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PetVivo Holdings Inc (PETV)?
The price-to-sales ratio of PetVivo Holdings Inc is 24.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PetVivo Holdings Inc (PETV)?
Earnings per share at PetVivo Holdings Inc are $−0.3300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of PetVivo Holdings Inc (PETV)?
The dividend yield of PetVivo Holdings Inc is 1.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of PetVivo Holdings Inc (PETV)?
The return on equity (ROE) of PetVivo Holdings Inc is −384% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PetVivo Holdings Inc (PETV)?
On an EBIT basis the return on assets of PetVivo Holdings Inc is −216% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PetVivo Holdings Inc (PETV)?
The operating margin of PetVivo Holdings Inc is −477% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PetVivo Holdings Inc (PETV)?
Revenue at PetVivo Holdings Inc is growing +13.5% versus a year earlier (3y avg +7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does PetVivo Holdings Inc (PETV) generate?
The free cash flow of PetVivo Holdings Inc is −$6.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does PetVivo Holdings Inc (PETV) carry?
The net debt of PetVivo Holdings Inc is $175K (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch PetVivo Holdings Inc in the live analysis

One click puts PetVivo Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.